Literature DB >> 19890696

Validation of the pepsinogen test method for gastric cancer screening using a follow-up study.

Shigeto Mizuno1, Masao Kobayashi, Shohken Tomita, Ikuya Miki, Atsuhiro Masuda, Mitsuko Onoyama, Yasuki Habu, Hideto Inokuchi, Yoshiyuki Watanabe.   

Abstract

BACKGROUND: Serum pepsinogen (PG) measurement has been used for gastric cancer screening since the 1990s. However, there are no reports comparing the screening validity of the PG test method with that of conventional X-ray examination directly in the same population, using a follow-up study.
METHODS: From April 2000 to March 2001, 12 120 residents of Osaka Prefecture, who underwent opportunistic screening at a medical checkup organization in Osaka city (hereafter, "the organization"), were enrolled. They received both a barium meal examination and PG test simultaneously. All the participants were followed up for a 1-year period after the screening. For the participants advised to undergo endoscopic examination, the results of those who were examined at the organization were tallied. The other participants were checked using the Osaka Cancer Registry (hereafter, "the registry").
RESULTS: Of the 12 120 participants, 493 (4.1%) were positive with the PG method and 728 (6.0%) were positive with the X-ray method. Fifty-four (0.4%) were positive for both methods. Thirteen gastric cancer cases were diagnosed by successive esophagogastroduodenoscopies at the organization. Six additional gastric cancer cases were identified by record linkage with the registry. The sensitivity, specificity, and positive predictive values of the PG method with a PGI cutoff level of <or=30 ng/ml and PGI/PGII ratio of <or=2.0 were 36.8%, 96.0%, and 1.4%, respectively. These values for the direct X-ray examination were 68.4%, 94.1%, and 1.8%, respectively.
CONCLUSION: The PG test method alone with a PGI cutoff level of <or=30 ng/ml and PGI/PGII <or= 2.0 is not appropriate for gastric cancer screening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890696     DOI: 10.1007/s10120-009-0522-y

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  23 in total

1.  Estimation of validity of mass screening program for gastric cancer in Osaka, Japan.

Authors:  R Murakami; H Tsukuma; T Ubukata; K Nakanishi; I Fujimoto; T Kawashima; H Yamazaki; A Oshima
Journal:  Cancer       Date:  1990-03-01       Impact factor: 6.860

2.  Evaluation of a mass screening program for stomach cancer with a case-control study design.

Authors:  A Oshima; N Hirata; T Ubukata; K Umeda; I Fujimoto
Journal:  Int J Cancer       Date:  1986-12-15       Impact factor: 7.396

3.  Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence.

Authors:  I M Samloff; W M Liebman
Journal:  Gastroenterology       Date:  1973-07       Impact factor: 22.682

4.  Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach.

Authors:  K Kimura
Journal:  Gastroenterology       Date:  1972-10       Impact factor: 22.682

5.  Serum pepsinogens as a screening test of extensive chronic gastritis.

Authors:  K Miki; M Ichinose; A Shimizu; S C Huang; H Oka; C Furihata; T Matsushima; K Takahashi
Journal:  Gastroenterol Jpn       Date:  1987-04

6.  The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study.

Authors:  A Fukao; Y Tsubono; I Tsuji; S HIsamichi; N Sugahara; A Takano
Journal:  Int J Cancer       Date:  1995-01-03       Impact factor: 7.396

7.  Usefulness of gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki; Masuo Morita; Masahiko Sasajima; Reiko Hoshina; Eiko Kanda; Yoshihisa Urita
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

8.  Serum pepsinogen in screening for gastric cancer.

Authors:  A Kodoi; M Yoshihara; K Sumii; K Haruma; G Kajiyama
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

9.  Serum pepsinogen I as a predictor of stomach cancer.

Authors:  A M Nomura; G N Stemmermann; I M Samloff
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

10.  The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects.

Authors:  K Miki; M Ichinose; N Kawamura; M Matsushima; H B Ahmad; M Kimura; J Sano; T Tashiro; N Kakei; H Oka
Journal:  Jpn J Cancer Res       Date:  1989-02
View more
  19 in total

1.  Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection.

Authors:  Sohachi Nanjo; Kiyoshi Asada; Satoshi Yamashita; Takeshi Nakajima; Kazuyuki Nakazawa; Takao Maekita; Masao Ichinose; Toshiro Sugiyama; Toshikazu Ushijima
Journal:  Gastric Cancer       Date:  2012-01-12       Impact factor: 7.370

2.  Serum pepsinogens in gastric cancer screening.

Authors:  Pelayo Correa
Journal:  Dig Dis Sci       Date:  2010-08       Impact factor: 3.199

Review 3.  Implementation of gastric cancer screening - the global experience.

Authors:  Mārcis Leja; Weicheng You; M Constanza Camargo; Hiroshi Saito
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-09-28       Impact factor: 3.043

4.  Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.

Authors:  Jennifer M Yeh; Chin Hur; Zachary Ward; Deborah Schrag; Sue J Goldie
Journal:  Gut       Date:  2015-03-16       Impact factor: 23.059

Review 5.  Gastric cancer: prevention, screening and early diagnosis.

Authors:  Victor Pasechnikov; Sergej Chukov; Evgeny Fedorov; Ilze Kikuste; Marcis Leja
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

6.  First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.

Authors:  Yoshimasa Saito; Hiroshi Serizawa; Yukako Kato; Masaru Nakano; Masahiko Nakamura; Hidetsugu Saito; Hidekazu Suzuki; Takanori Kanai
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

7.  Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study.

Authors:  Huakang Tu; Liping Sun; Xiao Dong; Yuehua Gong; Qian Xu; Jingjing Jing; Qi Long; W Dana Flanders; Roberd M Bostick; Yuan Yuan
Journal:  Int J Cancer       Date:  2014-06-19       Impact factor: 7.396

Review 8.  Emerging blood-based biomarkers for detection of gastric cancer.

Authors:  Zane Kalniņa; Irēna Meistere; Ilze Kikuste; Ivars Tolmanis; Pawel Zayakin; Aija Linē
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

9.  Serological assessment of gastric mucosal atrophy in gastric cancer.

Authors:  Jan Bornschein; Michael Selgrad; Thomas Wex; Doerthe Kuester; Peter Malfertheiner
Journal:  BMC Gastroenterol       Date:  2012-01-31       Impact factor: 3.067

Review 10.  Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis.

Authors:  Ya-kai Huang; Jian-chun Yu; Wei-ming Kang; Zhi-qiang Ma; Xin Ye; Shu-bo Tian; Chao Yan
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.